{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:12:50Z","timestamp":1765609970991,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00768","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T04:37:07Z","timestamp":1562733427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Drug Safety Warnings and Cost-Sharing Policies on Osteoporosis Drug Utilization in Spain: A Major Reduction But With the Persistence of Over and Underuse. Data From the ESOSVAL Cohort From 2009 to 2015"],"prefix":"10.3389","volume":"10","author":[{"given":"Isabel","family":"Hurtado-Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u00edbal","family":"Garc\u00eda-Sempere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Rodr\u00edguez-Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Sanf\u00e9lix-Genov\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Peir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Sanf\u00e9lix-Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"B1","unstructured":"Institute for Clinical Systems Improvement. Diagnosis and Treatment of Osteoporosis\n            AllenS.\n            Forney-GormanA.\n            HomanM.\n            KearnsA.\n            KramlingerA.\n            SauerM.\n          2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jsps.2017.12.005","article-title":"Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication","volume":"26","author":"Balkhi","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1210\/jc.2009-2157","article-title":"Disparate outcomes from applying U.K","volume":"95","author":"Bolland","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"National Osteoporosis Guideline Group (NOGG)","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"National Osteoporosis Foundation","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e180826","DOI":"10.1001\/jamanetworkopen.2018.0826","article-title":"Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures","volume":"1","author":"Desai","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamainternmed.2015.6020","article-title":"Osteoporosis overtreatment in a regional health care system","volume":"176","author":"Fenton","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/heartjnl-2016-310610","article-title":"Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome","volume":"103","author":"Gonz\u00e1lez L\u00f3pez-Valc\u00e1rcel","year":"2017","journal-title":"Heart"},{"key":"B9","doi-asserted-by":"publisher","first-page":"862.e1","DOI":"10.1016\/j.amjmed.2017.03.002","article-title":"Western Osteoporosis Alliance Clinical Practice Series: evaluating the balance of benefits and risks of long-term osteoporosis therapies","volume":"130","author":"Hanley","year":"2017","journal-title":"Am. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1210\/jc.2013-3448","article-title":"Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain","volume":"99","author":"Hurtado","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2088","article-title":"Overdiagnosis of bone fragility in the quest to prevent hip fracture","volume":"350","author":"J\u00e4rvinen","year":"2015","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","article-title":"IOF Working Group on Epidemiology and Quality of Life","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.01.014","article-title":"Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study","volume":"128","author":"Kim","year":"2015","journal-title":"Am. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/jbmr.2832","article-title":"Impact of the U.S","volume":"31","author":"Kim","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/s-0042-107671","article-title":"Osteoporosis management in a real clinical setting: heterogeneity in intervention approach and discrepancy in treatment rates when compared with the NOGG and NOF guidelines","volume":"124","author":"Kyriakos","year":"2016","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bone.2017.08.031","article-title":"Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up","volume":"105","author":"Mart\u00edn-Merino","year":"2017","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 Clinical Practice Guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/pds.3703","article-title":"Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy","volume":"23","author":"Peeters","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B23","unstructured":"Extent and causes of international variations in drug usage. A report for the Secretary of State for Health by Professor Sir Mike Richards CBE\n            RichardsM.\n          London, UKCentral Office of Information2010"},{"key":"B24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.maturitas.2012.10.002","article-title":"Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008","volume":"74","author":"Salgueiro","year":"2013","journal-title":"Maturitas"},{"key":"B26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2458-10-153","article-title":"Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study","volume":"10","author":"Sanf\u00e9lix-Genov\u00e9s","year":"2010","journal-title":"BMC Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00198-012-2018-6","article-title":"Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain","volume":"24","author":"Sanf\u00e9lix-Genov\u00e9s","year":"2013","journal-title":"Osteoporos Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.medcli.2012.10.025","article-title":"Variability in the recommendations for the clinical management of osteoporosis","volume":"142","author":"Sanf\u00e9lix-Genov\u00e9s","year":"2014","journal-title":"Med. Clin. (Barc.)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/jbmr.1977","article-title":"Prevalence, determinants, and inappropriateness of calcium supplementation among men and women in a Spanish Mediterranean area: cross-sectional data from the ESOSVAL cohort","volume":"28","author":"Sanf\u00e9lix-Gimeno","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135475","article-title":"Overuse and underuse of antiosteoporotic treatments according to highly influential osteoporosis guidelines: a population-based cross-sectional study in Spain","volume":"10","author":"Sanf\u00e9lix-Gimeno","year":"2015","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/nejmoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"EU review panel of IOF","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"B33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","article-title":"Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity","volume":"94","author":"van der Velde","year":"2017","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cen.13000","article-title":"Management recommendations for osteoporosis in clinical guidelines","volume":"84","author":"Wang","year":"2016","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/nejmp1202619","article-title":"Bisphosphonates for osteoporosis\u2013where do we go from here","volume":"366","author":"Whitaker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/nejmc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use","volume":"360","author":"Wysowski","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T04:37:10Z","timestamp":1562733430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":37,"alternative-id":["10.3389\/fphar.2019.00768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"article-number":"768"}}